Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04565717 · ClinicalTrials.gov registry record · Phase 1
A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH)
A Phase 1 study, sponsored by Alnylam Pharmaceuticals.
- Terminated
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
NCT04565717 is a Phase 1 study that was terminated before completion, run by Alnylam Pharmaceuticals. The registered enrollment target is 6 participants.
The verdict
NCT04565717, a Phase 1 study, was terminated before completion, sponsored by Alnylam Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and tolerability of single ascending doses of ALN-HSD in healthy participants (Part A) and multiple doses of ALN-HSD in patients with NASH (Parts B and C).
Interventions
- DRUG Placebo
- DRUG ALN-HSD
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2020-10-09 |
| Est. Completion | 2023-12-21 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04565717
The ClinicalTrials.gov registry entry for NCT04565717 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alnylam Pharmaceuticals, which has 49 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04565717 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04565717 about?
NCT04565717 is a clinical study titled "A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH)". The purpose of this study is to evaluate the safety and tolerability of single ascending doses of ALN-HSD in healthy participants (Part A) and multiple doses of ALN-HSD in patients with NASH (Parts B and C).
What is the current status of trial NCT04565717?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2020-10-09. Estimated completion is 2023-12-21.
What interventions are being tested in trial NCT04565717?
The interventions under investigation include: Placebo (DRUG), ALN-HSD (DRUG).
Who is sponsoring clinical trial NCT04565717?
This trial is sponsored by Alnylam Pharmaceuticals, which has 49 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.